Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO
A US listing for the oncology specialist continues a bumper year for biotech IPOs.
Featured s
Roche’s Tecentriq snags FDA label expansion in type of colon cancer
Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher…
All Articles
Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO
A US listing for the oncology specialist continues a bumper year for biotech IPOs.
Roche’s Tecentriq snags FDA label expansion in type of colon cancer
Tecentriq is now the first immunotherapy indicated for dMMR colon cancer treatment specifically, which is often linked to a higher…
Bio-Techne opens GMP small molecule facility in Bristol, UK
The purpose-built site is fully operational and produces materials to support developers working on cell therapies globally.
Biohaven partners with Ono in $100m IgG degrader deal
The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan.
Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout
The non-opioid pain space is attracting increasing attention as experts sound the alarm on dependency issues linked to long-term opioid-based…
Change lifestyle before giving children weight loss medication, WHO says
In its first global guidelines for child and adolescent obesity, the WHO says diet, exercise, and behavioural changes should be…
FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer
Regulatory clearance was based on findings from the double-blind, placebo-controlled Phase III HER2CLIMB-05 trial.
CPHI 2026: Finding the right CDMO partner in an age of consolidation
Executives from companies such as Leo Pharma and Daiichi Sankyo debated outsourcing selections and whether size is better in manufacturing.
Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed
Experts discuss the latest research released at EASD 2026 and what it could mean for the diabetes community.
10x Genomics and Fred Hutch partner on cancer technologies
The initiative represents the first time 10x Genomics widened its scope past solid tumours to include haematologic malignancies.